Top 5 Forestry Companies To Buy For 2014

The Motley Fool's readers have spoken, and I have heeded your cries. After months of pointing out�CEO gaffes�and faux pas, I've decided to make it a weekly tradition to also point out corporate leaders who are putting the interests of shareholders and the public first and are generally deserving of praise from investors. For reference, here's�my previous selection.

This week, I'll turn your attention to my selection for CEO of the year in 2011, Ajay Banga, CEO of MasterCard (NYSE: MA  ) .

Kudos to you, Mr. Banga
There isn't much not to like about MasterCard's business model or the direction Ajay Banga has taken the company since he became CEO in July 2010.

The biggest concern for the two largest credit card processing companies -- MasterCard and Visa (NYSE: V  ) �-- is whether or not consumer spending is growing or slowing. If global dollars transacted and volumes are falling, that would mean less processing revenue for these giants. However, I can't actually recall the last time we saw a steady decline in credit card usage since the deep recession of 2009.

Best Up And Coming Companies To Invest In Right Now: NovaDx Ventures Corp (NDX)

NovaDX Ventures Corp. (Novadx) is a Canada-based mining investment company, engaged in investing in the North American junior resource exploration and mining sector. In January, 2012 a higher capacity auger machine was delivered to the Rosa Mine. During August 2012, the Company sold the small auger and paid off the higher capacity auger machine. On October 16, 2012,the Company announced that it, along with Sandstorm, have entered into a Letter of Intent to acquire certain coal properties and assets located in Campbell and Scott Counties, Tennessee. The Company�� wholly owned subsidiary MCoal Corporation (MCoal) operates the Rosa mine located in Blount Count, Alabama, which produces coal for the metallurgical and activated carbon coal markets. In January 2013, Sandstorm Metals and Energy Ltd together with the Company acquired Mine 12, the Turley Rail Load-Out, and the Smokey Junction Preparation Plant located in Campbell and Scott Counties, Tennessee. Advisors' Opinion:

• [By Jim Jubak]

  However, in all fairness, shares of Qualcomm have indeed lagged the Nasdaq 100 (NDX) over the past year. But despite that fact, Qualcomm is still currently rated a buy by a large percentage of analysts who continue to follow the stock. As Hendershot points out, perhaps that is because ��ualcomm believes the company can generate double-digit compound average growth for revenues and earnings for, at least, the next five years.��/p>

Top 5 Forestry Companies To Buy For 2014: Pain Therapeutics Inc (PTIE)

Pain Therapeutics, Inc., incorporated in May 1998, is a biopharmaceutical company that develops drugs. The Company has four drug candidates in clinical programs, including REMOXY, abuse-resistant hydromorphone, abuse-resistant hydrocodone and a radio-labeled monoclonal antibody to treat metastatic melanoma. It is also working on a new treatment for patients with hemophilia. The Company�� lead drug candidate is REMOXY, which is a painkiller. It has collaboration agreement with King Pharmaceuticals, Inc. (King) develops and commercializes REMOXY and other opioid painkillers. The Company and King jointly managed a Phase III clinical program and New Drug Application (NDA) submission for REMOXY. It is also developing a pipeline of drug candidates in the area of oncology and hematology. It owns all commercial rights to its pipeline of drug candidates in oncology and hematology. As of December 31, 2010, the Company leased approximately 30,700 square feet of space in San Mateo, California and all of its operations are located in San Mateo.

REMOXY

REMOXY is a controlled-release oral capsule form of oxycodone in a highly viscous liquid formulation matrix that includes excipients. It is formulated to help address issues of abuse and misuse of time-release oxycodone tablets. REMOXY�� capsule dosage form provides therapeutic drug levels of oxycodone on a twice-daily dosing schedule, while resisting the rapid increases in plasma levels of oxycodone associated with common methods of abuse and misuse. Its formulation also resists delivery by unapproved routes of administration, such as injection, snorting or inhalation.

Metastatic Melanoma

The Company is developing a drug candidate called PTI-188 to treat metastatic melanoma, a form of skin cancer. PTI-188 is a monoclonal antibody linked to a radioisotope, intended to deliver doses of radiation lethal to melanoma tumors without harming normal tissue. In March 2010, the Company announced data from two open-label! , dose-escalating Phase I studies conducted in Israel to assess the safety, pharmacokinetics, dosimetry and anti-tumor activity of PTI-188. During the year ended December 31, 2010, the second study was completed. The technology used in this program was developed at the Albert Einstein College of Medicine (AECOM). It had licensed worldwide commercial rights to this technology from AECOM.

Hemophilia

The Company has a gene transfer program, initially developed at Stanford University, focused at correcting a genetic disorder in which patients are unable to stop bleeding. During 2010, it conducted a variety of pre-clinical studies with this technology. The Company has licensed worldwide commercial rights to the technology used in this program from Poetic Genetics, LLC (Poetic).

Other product candidates

The Company�� alliance with King includes development of three other abuse-resistant opioid product candidates: hydromorphone, hydrocodone and oxymorphone. Its abuse-resistant formulations of hydromorphone and hydrocodone have completed Phase I clinical trials. In January 2011, the Company announced that the Food and Drug Administration (FDA) had accepted its investigational IND, for abuse-resistant oxymorphone.

The Company competes with Roxane Laboratories, Purdue Pharma, King Pharmaceuticals, Inc., Abbott Laboratories, Cephalon, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals.

Advisors' Opinion:

• [By Sean Williams]

  However, all isn't well when it comes to the future of abuse-resistant painkiller Remoxy, which was developed by Pain Therapeutics (NASDAQ: PTIE  ) , using Durect's�special technology-based gel capsule to prevent abuse, and is licensed by Pfizer (NYSE: PFE  ) . Remoxy has been rejected twice by the FDA -- the most recent coming in mid-2011 -- and Pfizer commented this morning that if it were to seek reapproval for the drug it wouldn't be for at least two more years. Given Pfizer's extensive product pipeline, losing Remoxy wouldn't be a big deal. For micro-cap clinical-stage companies like Pain Therapeutics and Durect, it'd be a gigantic blow. Fittingly, Pain Therapeutics and Durect shares imploded by 50% and 34%, respectively, on Friday.

• [By Jessica Alling]

  Elsewhere, Pfizer is evaluating its continued partnership on an experimental oxycodone capsule, Remoxy. The drug is an extended-release formula that is targeted at reducing abuse of the painkiller. After years of setbacks and postponements for FDA approval, Pfizer is weighing its options. Its partners for the drug, Pain Therapeutics (NASDAQ: PTIE  ) and Durect, have both fallen heavily due to the news, with Pain Therapeutics falling more than 50% -- its largest decline ever.

Top 5 Forestry Companies To Buy For 2014: Deltathree Inc (DDDC)

deltathree, Inc. (deltathree), incorporated January 27, 1998, is a provider of integrated video and voices over Internet Protocol (VoIP), telephony services, products, hosted solutions and infrastructure. deltathree offers a range of private label VoIP products and services, as well as back-office platforms. The Company's operations management tools include account provisioning; e-commerce-based payment processing systems; billing and account management; operations management; Web development; network management; and customer care. The Company's direct-to-consumer channel includes its joip Mobile application, iConnectHere offering (which provides VoIP products and services directly to consumers and small businesses online using the same primary platform) and its joip offering (which serves as the exclusive VoIP service provider embedded in the Globarange cordless phones of Panasonic Communications).

Products

Deltathree�� products include joip Mobile Application, Digital Video and Voice-over-IP Services, Broadband Phone and personal computer (PC)-to-Phone. The Company's joip Mobile application is a cellular phone application providing low cost mobile calls over third-generation (3G) cellular networks, as well as wireless fidelity (WiFi) networks. Cellular operating systems supported by joip Mobile include the iPhone, Google Android. Nokia Symbian and Blackberry. Through the use of the Company's network it offers a white-label solution in which its customers have the ability to customize, implement and rapidly launch digital next generation communications offerings with minimal risk and investment. For the Company's potential partners, the Company offers a range of service provider back-end support services, including network management, billing, provisioning, e-commerce, as well as custom Web and application development.

The Company's Broadband Phone product is a phone replacement solution available to business and retail customers over the last mile through br! oadband connections through cable modem, digital subscriber line (DSL) or fixed wireless. Broadband Phone enables a user to conveniently operate features and retrieve voice mail through e-mail, Web or a phone interface. The Company's PC-to-Phone offering enables a user to conveniently and inexpensively place a call to a standard telephone anywhere in the world directly from a personal computer while remaining on-line.

Services

deltathree operations management tools include video mail, account provisioning, payment processing systems, billing and account management, customer care and network operations care. The Company provides a video mail feature for its video phones applications. The Company provides its service provider and reseller customers with a Web page through which it can order additional services or accounts, generate and activate PINs and perform other customary implementation functions. It provides the customers with a fraud detection and prevention system to permits secure credit card transactions over the Web.

The Company provides the customers with real-time, Web-based access to billing records to check billing and usage information or to increases prepaid accounts. It has moved and consolidated traditional first tiers customer care functions onto the Web for ease and flexibility and support this with second tier customer care. The Company provides a Network Operations Center (NOC), automated troubles ticket system, which enables its customers to submit, manage, and follow-up with technical questions and issues online. The provision of VoIP products and services through the Company's service provider and reseller sales channel and its direct-to-consumer channel accounted for 75.4% and 23.3% of its total revenues during 2011, respectively.

Advisors' Opinion:

• [By John Udovich]

  Bardin, who previously ran online-video startup Intercast Networks and co-founded online-calling service Deltathree Inc. (DDDC), has increased his presence in the Israeli startup scene in recent years, speaking at conferences and appearing at technology-industry events.

Top 5 Forestry Companies To Buy For 2014: THERMOGENESIS Corp.(KOOL)

ThermoGenesis Corp. designs, develops, and sells medical products that enable the practice of regenerative medicine worldwide. It offers automated and semi-automated devices, and single-use processing disposables that enable the collection, processing, and cryopreservation of stem cells and other cellular tissues used in the practice of regenerative medicine. Regenerative medicine is a field that uses cell-based therapies to repair or restore lost or damaged tissue and cell function. The company?s products include the AXP System, a medical device that isolates and retrieves stem cells from umbilical cord blood; the BioArchive System, a robotic cryogenic medical device used by cord blood banks for the cryopreservation and archiving of cord blood stem cell units for transplant; the MarrowXpress or MXP System that isolates and concentrates stem cells from bone marrow; Res-Q 60 BMC, a point-of-care bone marrow stem cell processing system; and Res-Q 60 PRP, which is used for t he preparation of autologous platelet rich plasma from a sample of blood at the point of care. It also offers ThermoLine product line, which includes ultra-rapid plasma ThermoLine Freezer and ultra-rapid plasma ThermoLine Thawer; and CryoSeal System, an automated system, which is used to prepare an autologous hemostatic surgical sealant. ThermoGenesis Corp. was founded in 1986 and is based in Rancho Cordova, California.

Advisors' Opinion:

• [By John Udovich]

  The controversy over stem cell research or their usage seems to have ebbed in recent years as stem cell science moves beyond the use of embryos and lately there has been a steady flow of overlooked good news from the sector or from small cap stem cell stocks like Cellular Dynamics (which will IPO soon), ThermoGenesis Corp (NASDAQ: KOOL) and BioRestorative Therapies (OTCBB: BRTX) for investors to digest. Just consider the following news:

• [By Monica Gerson]

  ThermoGenesis (NASDAQ: KOOL) moved up 29.81% to $2.9857. ThermoGenesis' trailing-twelve-month revenue is $17.49 million.

  Infosonics (NASDAQ: IFON) shares jumped 22.64% to $2.06. Infosonics shares have jumped 170.97% over the past 52 weeks, while the S&P 500 index has gained 23.35% in the same period.